Be Ready to Dispense Paxlovid or Molnupiravir for COVID-19
February 2022
You'll start to see Rxs for two new oral antivirals to treat COVID-19, Paxlovid (nirmatrelvir/ritonavir) or molnupiravir.
Either is an option for patients with mild to moderate COVID-19 who are at high risk of developing serious illness (age 65 or older, diabetes, etc)...regardless of vaccination status.
Be ready to handle these Rxs correctly...and ensure safe use.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote